Literature DB >> 4015915

Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment.

A D Timmis, P Smyth, D E Jewitt.   

Abstract

The effects of milrinone, a new bipyridine inotropic agent, on the haemodynamic responses to treadmill exercise were studied in 12 patients with congestive heart failure. Four weeks' treatment with milrinone 20 mg daily produced an improvement in left ventricular function during exercise as reflected by significant increments in cardiac index and stroke volume index without change in pulmonary capillary wedge pressure. Systemic oxygen consumption, measured at submaximal exercise, also increased suggesting that the drug induced rise in stroke output was associated with improved skeletal muscle perfusion. Maximum exercise capacity increased. Importantly, the beneficial effects of milrinone on exercise haemodynamics and exercise tolerance were sustained throughout the four week treatment period. No drug related side effects occurred. After treatment with milrinone was stopped left ventricular function deteriorated to a level slightly, but significantly, worse than that before treatment. These observations indicate a potentially useful role for milrinone in treating heart failure.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015915      PMCID: PMC481846          DOI: 10.1136/hrt.54.1.42

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  22 in total

1.  Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.

Authors:  M Packer; J Meller; R Gorlin; M V Herman
Journal:  Circulation       Date:  1979-03       Impact factor: 29.690

2.  A new inotropic drug: its promise and a caution.

Authors:  A M Katz
Journal:  N Engl J Med       Date:  1978-12-21       Impact factor: 91.245

3.  Exercise capacity in patients with severe left ventricular dysfunction.

Authors:  W Benge; R L Litchfield; M L Marcus
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

4.  Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators.

Authors:  S A Rubin; K Chatterjee; W W Parmley
Journal:  Circulation       Date:  1980-03       Impact factor: 29.690

5.  Some statistical methods useful in circulation research.

Authors:  S Wallenstein; C L Zucker; J L Fleiss
Journal:  Circ Res       Date:  1980-07       Impact factor: 17.367

6.  Functional capacity of patients with chronic left ventricular failure. Relationship of bicycle exercise performance to clinical and hemodynamic characterization.

Authors:  J A Franciosa; S Ziesche; M Wilen
Journal:  Am J Med       Date:  1979-09       Impact factor: 4.965

7.  Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.

Authors:  W S Colucci; R W Alexander; G H Williams; R E Rude; B L Holman; M A Konstam; J Wynne; G H Mudge; E Braunwald
Journal:  N Engl J Med       Date:  1981-07-23       Impact factor: 91.245

8.  Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease.

Authors:  J R Benotti; W Grossman; E Braunwald; B A Carabello
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

9.  Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease.

Authors:  C S Maskin; R Forman; N A Klein; E H Sonnenblick; T H LeJemtel
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965

10.  Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure.

Authors:  J A Franciosa; J N Cohn
Journal:  Am J Cardiol       Date:  1979-05       Impact factor: 2.778

View more
  4 in total

Review 1.  Adverse effects associated with the newer inotropic agents.

Authors:  M W Webster; D N Sharpe
Journal:  Med Toxicol       Date:  1986 Sep-Oct

Review 2.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

3.  Drug therapy of chronic heart failure.

Authors:  Stanley H Taylor
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

Review 4.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.